FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

Data Compilation
#PharmaFlow

Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

Stock Recap
#PipelineProspector

ATAZANAVIR SULPHATE

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

41 API Suppliers, 24 USDMF, 6 CEP/COS, 10 EU WC, 1 KDMF, 15 NDC API, 20 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

91 FDF Dossiers, 42 FDA Orange Book, 30 Europe, 11 Canada, 2 South Africa, 6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG, CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 200MG BASE, CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 SPI Pharma, 5 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 2 Kirsch Pharma, 4 ACG Worldwide, 1 Actylis, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 6 DFE Pharma, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures, 2 Ingredion Pharma Solutions, 10 Kerry, 3 Keval Exports, 3 Lonza Capsugel, 12 Microlex e.U, 1 Neelkanth MineChem, 2 Nitika Pharmaceutical Specialities, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 14 Roquette, 3 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 4 Silverline Chemicals, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

30 Fillers, Diluents & Binders, 22 Disintegrants & Superdisintegrants, 18 Granulation, 18 Thickeners and Stabilizers, 16 Lubricants & Glidants, 15 Direct Compression, 11 Coating Systems & Additives, 8 Film Formers & Plasticizers, 8 Empty Capsules, 8 Emulsifying Agents, 8 Co-Processed Excipients, 7 Taste Masking, 7 Topical, 4 Solubilizers, 4 Controlled & Modified Release, 4 Chewable & Orodispersible Aids, 4 Parenteral, 3 Surfactant & Foaming Agents, 2 Rheology Modifiers, 1 API Stability Enhancers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 10 News #PharmaBuzz

GLOBAL SALES INFORMATION

9 US Medicaid Prescriptions, 5 Annual Reports

MARKET PLACE

1 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 12 Health Canada Patents

REF. STANDARDS & IMPURITIES

7 USP, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Labeler	NDC Package Code	Non Proprietary Name	Start Marketing Date	End Marketing Date	Category Code	Dosage Form (Strength)
27/02/2026	Granules India Limited	India	Granules India Ltd	62207-005	Atazanavir Sulfate	2018-06-11	2026-12-31	DRUG FOR FURTHER PROCESSING	POWDER (25kg/25kg)
27/02/2026	Honour Lab Limited	India	Honour Lab Limited	69037-0063	Atazanavir Sulfate	2003-06-20	2027-12-31	BULK INGREDIENT	POWDER (1kg/kg)

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

ATAZANAVIR SULPHATE

ATAZANAVIR SULPHATE

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

41 API Suppliers

24 USDMF

6 CEP/COS

10 EU WC

1 KDMF

15 NDC API

20 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

91 FDF Dossiers

42 FDA Orange Book

30 Europe

11 Canada

2 South Africa

6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 300MG BASE;150MG

CAPSULE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 200MG BASE

CAPSULE;ORAL - EQ 300MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

1 SPI Pharma

5 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Pfanstiehl

2 Kirsch Pharma

4 ACG Worldwide

1 Actylis

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

8 BASF

6 DFE Pharma

1 Finar

6 Gangwal Chemicals

1 Ideal Cures

2 Ingredion Pharma Solutions

10 Kerry

3 Keval Exports

3 Lonza Capsugel

12 Microlex e.U

1 Neelkanth MineChem

2 Nitika Pharmaceutical Specialities

2 Pharmatrans-Sanaq

4 Pluviaendo

4 Prachin Chemical

1 Qualicaps

14 Roquette

3 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

10 Sigachi Industries

4 Silverline Chemicals

1 Valens Pharmachem

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

30 Fillers, Diluents & Binders

22 Disintegrants & Superdisintegrants

18 Granulation

18 Thickeners and Stabilizers

16 Lubricants & Glidants

15 Direct Compression

11 Coating Systems & Additives

8 Film Formers & Plasticizers

8 Empty Capsules

8 Emulsifying Agents

8 Co-Processed Excipients

7 Taste Masking

7 Topical

4 Solubilizers

4 Controlled & Modified Release

4 Chewable & Orodispersible Aids

4 Parenteral

CAPSULE;ORAL - EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons